Back to top
more

Dentsply Sirona (XRAY)

(Real Time Quote from BATS)

$25.58 USD

25.58
771,637

+0.27 (1.07%)

Updated Aug 26, 2024 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (188 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intuitive Surgical (ISRG) Q2 Earnings Beat, Guidance Narrowed

by Zacks Equity Research

Intuitive Surgical (ISRG) expects 2019 procedure growth within 16-17%.

Will 2-Pronged Plan Aid Quest Diagnostics (DGX) Q2 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) frequent partnership wins with health care leaders and sensible buyouts are creating bountiful opportunities for the top and the bottom line.

BioTelemetry (BEAT) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

BioTelemetry's (BEAT) strong second-quarter 2019 expectations are indicative of solid results.

What's in Store for Edwards Lifesciences' (EW) Q2 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) is likely to deliver a solid second quarter on robust segmental performance.

Here's Why Investors Should Consider Cerner (CERN) Stock

by Zacks Equity Research

For the second quarter, Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion.

Falling Earnings Estimates Signal Weakness Ahead for Patterson Companies (PDCO)

by Zacks Equity Research

Patterson Companies (PDCO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Aniruddha Ganguly headshot

7 S&P 500-Beating Stocks to Buy Ahead of Q2 Earnings

by Aniruddha Ganguly

Here we pick seven stocks that have outperformed the S&P 500 and are likely to beat earnings estimates this reporting cycle.

Can Global Industrial Unit Drive Ecolab's (ECL) Q2 Earnings?

by Zacks Equity Research

Ecolab (ECL) likely to see impressive growth in second-quarter adjusted earnings per share.

Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?

by Zacks Equity Research

Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.

McKesson (MCK) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Top-line growth and better-than-expected segmental performance are likely to aid McKesson (MCK) in Q1. However, rise in adjusted operating expenses is likely to be a dampener.

Can Instruments Drive Intuitive Surgical (ISRG) Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical (ISRG) expects its core Instruments and Accessories unit to boost second-quarter 2019 results.

AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates

by Zacks Equity Research

AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.

Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio

by Zacks Equity Research

With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.

Varian to Acquire Boston Scientific's Embolic Bead Products

by Zacks Equity Research

Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.

Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues

by Zacks Equity Research

Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.

Medtronic's Titan Spine Buyout to Boost Spine Surgery Range

by Zacks Equity Research

Medtronic's (MDT) comprehensive biologics portfolio clubbed with Titan Spine's surface-enhanced titanium implants can enhance patient outcomes in spinal procedures.

Walgreens Gains on Strategic Deals, Margin Pressure Remains

by Zacks Equity Research

Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.

Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics

by Zacks Equity Research

The Anatomical Pathology business of Thermo Fisher (TMO) belongs to its Specialty Diagnostics segment that serves customers across healthcare and clinical laboratories.

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Varian (VAR) expects the Cancer Treatment Services International buyout to prove accretive to earnings per share during fiscal 2021.

Amedisys Rides on New Buyouts, Strength in Personal Care Arm

by Zacks Equity Research

Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.

Veeva's Vault eTMF Implemented by South Korea's Celltrion

by Zacks Equity Research

Management at Veeva (VEEV) expects Vault subscription revenues to grow a significant 40% in fiscal 2020.

Patterson Companies' (PDCO) Earnings Miss Estimates in Q4

by Zacks Equity Research

Patterson Companies' (PDCO) Q4 results benefit from higher revenues, gross margin expansion and solid show by Animal Health segment.

Varian (VAR) & Tennessee Oncology to Implement Use of Noona

by Zacks Equity Research

Varian's (VAR) core Oncology unit gets a boost from the latest collaboration with Tennessee Oncology.

Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY (XRAY) focuses on innovation through active R&D.

Veeva's Submissions & RIM Implemented by Sumitomo Dainippon

by Zacks Equity Research

Veeva's (VEEV) flagship Vault platform witnesses robust demand.